Pre-made Samrotamab benchmark antibody ( Whole mAb ADC, anti-LRRC15 therapeutic antibody, Anti-LIB Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.
| Products Name (INN Index) | Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody |
|---|---|
| INN Name | Samrotamab |
| Target | LRRC15 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | AbbVie |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LRRC15 |
| Package |
